New Percutaneous Devices to Prevent Embolism in Atrial Fibrillation

Patients with atrial fibrillation (AF) unsuitable for anticoagulation because of bleeding risk, require other strategies to prevent stroke. For some years, there have been in the market (limited to some places; not as part of the regular agenda of cardiologists and hematologists) devices to occlude the atrium that have been proved safe and effective.

Proliferan los dispositivos para el reemplazo valvular mitral por catéter

These new devices are a completely different. They are permanent filters placed directly in both carotid arteries and are designed to capture >1.4 mm emboli.

This non-randomized, multicenter study has shown for the first time in humans the feasibility and safety of implanting this bilateral filter in patients with AF, high bleeding risk (CHA2DS2-VASc ≥ 2) unsuitable for anticoagulation, with common carotid arteries between 4.8 and 9.8 mm and stenosis < 30%.


Read also: The First Antidote Against Ticagrelor Is a Rapid-Acting, Extended Effect Agent in Preliminary Results.


Under ultrasound guidance and after direct puncture of the carotid with a 24 G needle, the filter is unfurled in the artery with a motorized system. All patients received aspirin and clopidogrel for 3 months, and aspirin thereafter.

Primary end points were procedural success (correct implantation of filter in both carotids) and composite of events at 30 days (death, stroke, major bleeding, filter migration, thrombus formation or stenosis). Ultrasound follow-up was carried out immediately after procedure, prior to discharge, at one week, one month and 3, 6 and 12 months.

The study included 25 patients with mean CHA2DS2-VASc of 4.4 ± 1, half of them had presented prior embolism.

Procedural success was 92%, in one patient, the device could be deployed only in one artery. There were no procedure related major events, only 20% of hematomas were puncture related.


Read also: El primer antídoto del ticagrelor es rápido y de acción prolongada en los resultados preliminares.


After 6 months, no patients formed thrombi inside the filter, but 4 did capture emboli (one bilateral); none of these patients developed symptoms.

In all patients, thrombi were reabsorbed using low molecular weight heparin for some time. There were 2 minor strokes, but not in carotid territory.

Conclusión

The implantation of permanent carotid filters to prevent strokes is technically feasible and safe.

Original Title: A Percutaneous Permanent Carotid Filter for Stroke Prevention in Atrial Fibrillation: The CAPTURE Trial.

Reference: Vivek Y et al. Journal of the American College of Cardiology (2019). ACCEPTED MANUSCRIPT.

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...